Abecma (idecabtagene vicleucel) received approval from the U.S. Food and Drug Administration (FDA) on March 26, 2021.

This article will inventory the anti-tumor targets in the GPCR family and the therapeutic drugs that have been marketed.

Azstarys was approved by the U.S. Food and Drug Administration (FDA) on March 2, 2021.

SciRhom GmbH has declared the successful conclusion of a EUR 63 million Series A funding round.

Fosdenopterin (Nulibry) was approved by the U.S. Food and Drug Administration (FDA) on February 26, 2021.

Jul 10th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Melphalan flufenamide (Pepaxto) was approved by the U.S. Food and Drug Administration (FDA) on February 26, 2021.

Immorna Biotherapeutics Gets U.S. FDA IND Approval for JCXH-211 IV Phase 1/2 Trial Alone and with Checkpoint Inhibitor in Advanced Solid Tumor Patients.

Casimersen was approved by the U.S. Food and Drug Administration (FDA) on February 25, 2021.

Mirum Pharmaceuticals, Inc. revealed that the European Commission has approved the marketing authorization for LIVMARLI® (maralixibat) oral solution

Trilaciclib was approved by the U.S. Food and Drug Administration (FDA) on February 12, 2021.

Regeneron Pharmaceuticals, Inc. and Sanofi announced today that the European Commission has granted approval for Dupixent (dupilumab) as an additional maintenance therapy for adults with uncontrolled chronic obstructive pulmonary disease with elevated blood eosinophils.